- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01968590
Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) (VitDBoneNF1)
A Phase II Trial on the Effect of Low-Dose Versus High-Dose Vitamin D Supplementation on Bone Mass in Adults With Neurofibromatosis Type 1 (NF1)
This clinical trial is conducted by one of 4 locations; University of British Columbia (Vancouver, CA), University of Utah (Salt Lake City, UT, USA), University of Cincinnati (Cincinnati, OH, USA), and University of Hamburg (Hamburg, Germany).
Adults with NF1 have a higher risk of osteopenia and osteoporosis, a condition of low bone density that can lead to fragile bones and bone breakage.
People with NF1 also have lower vitamin D levels than unaffected individuals. Vitamin D is important for normal bone health, but studies to improve bone health by vitamin D supplementation in people with NF1 have not been tried.
The purpose of this study is to treat adults with NF1 who have insufficient serum vitamin D levels with 2 different doses of vitamin D supplementation to determine if vitamin D supplementation ameliorates the usual loss of bone mineral density over 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Individuals with NF1 and vitamin D insufficiency will be supplemented with 2 different doses of cholecalciferol (vitamin D) to see if their loss of bone mineral density is lessened over time. It is important to study vitamins as carefully as one would study medications, even though vitamins are generally safer than medications. For this reason, a carefully controlled trial of two doses of vitamin D will be performed over a 2-year period. It will include controlled doses and safety checks for participants' health to be sure that the vitamin D supplementation is safe for people with NF1.
Two different doses of cholecalciferol, either 600 IU or 4,000 IU (IU means "International Units" a standard measure of the strength of the dose), will be used for supplementation. The trial is "double blind". This means that neither participant nor investigator team know which dose an individual participant might be randomized to receive until after the trial ends. In an emergency, however, the investigator can find out.
Participants will be randomized to one or the other dose, and each participant will be provided a bottle of liquid called "D-drops" with a dropper that automatically drops out a measured amount when the bottle is turned upside down.
Both doses of vitamin D, 600 IU and 4,000 IU, have been approved in the general population; however, it is possible that the bodies of people with NF1 handle vitamin D differently. Therefore, safety measures are assessed during this trial. Any new medical issues or concerns throughout the 2-year period will need to be recorded and assessed with the study team.
The primary measure of this study is bone mineral density obtained by bone densitometry (DXA) using low-dose xrays. Bone mineral density will be tested at the beginning and the end of the trial focusing on density of bones in the hip and spine. Secondary measures of this trial include questionnaires that measure quality of life and history of bone fractures.
When someone is insufficient in serum vitamin D and supplementation is recommended, it is also supplemented with calcium. Therefore, participants will be given a calcium supplement of 400 mg elemental calcium per day. A diary to keep daily track of vitamin D and calcium supplementation and documentation of fractures, should they occur, is provided.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z4
- University of British Columbia
-
-
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All individuals with NF1 (neurofibromatosis type 1), based on NIH diagnostic criteria, who are between the ages of 25 and 40 years, may participate in this study. All participants will be enrolled in the study and then screened for serum 25(OH)D levels, and all individuals with levels between 9 and 29ng/ml (inclusive) are eligible for vitamin D supplementation -
Exclusion Criteria:
- diagnosis of Paget's disease, hyperthyroidism, hyperparathyroidism, or other medical condition that affects bone health
- they foresee that they will be unable to comply with the two-year study protocol
- Pregnant, planning to conceive within the next two years, or is less than 6 months post-delivery or lactation.
- vitamin D supplementation in the last 3 months equal to or greater than 600IU per day
- oral or IV glucocorticoid use for over 3 months
- bisphosphonate therapy for more than 3 months
- calcitonin therapy for more than 3 months
- calcium supplementation in last 3 months equal to or greater than 1000mg per day
- malignant peripheral nerve sheath tumor (MPNST)
- history of kidney stones in last 5 years
- individuals with metal instrumentation in spine or hip that preclude accurate DXA interpretation.
- inability to obtain blood samples on routine venipuncture
- anti-epileptic medical therapy
- anticoagulant medical therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: cholecalciferol 600 IU
cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
|
DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose.
Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day.
There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
Other Names:
|
Active Comparator: cholecalciferol 4,000 IU
Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
|
DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose.
Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day.
There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone mineral density
Time Frame: Change from Day 1 to 2 years
|
The primary outcome measure is a change in bone mineral density, which will be determined by bone densitometry at the beginning and at the end of the 2-year trial.
|
Change from Day 1 to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone Fractures
Time Frame: change from Day 1 through 2 years
|
Secondary outcome measure of history of bone fractures.
|
change from Day 1 through 2 years
|
Quality of life questionnaires
Time Frame: change from Day 1 through 2 years
|
Secondary outcome measures include quality of life
|
change from Day 1 through 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parathyroid hormone with calcium
Time Frame: change from day1 through year 2
|
Serum samples will be analyzed for intact parathyroid hormone with calcium.
|
change from day1 through year 2
|
25(OH) vitamin D
Time Frame: change from day1 through year 2
|
Serum samples will be analyzed for 25(OH) vitamin D
|
change from day1 through year 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David H. Viskochil, MD, PhD, University of Utah
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- DoD A-17236
- W18XWH-12-1-0487 (Other Grant/Funding Number: Department of Defense NF Research Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurofibromatosis Type 1 (NF1)
-
SpringWorks Therapeutics, Inc.Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
AstraZenecaCompletedHealthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)United States
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Institute of Neurological Disorders and Stroke (NINDS); Children's...RecruitingNeurofibromatosis 1 | Neurofibromatosis Type 1 | NF1United States
-
Guy's and St Thomas' NHS Foundation TrustCompletedNeurofibromatosis 1, NF1United Kingdom
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 | Neurofibroma, Plexiform | Neurofibromatosis Type 1 | NF1United States
-
National Human Genome Research Institute (NHGRI)CompletedNeurofibromatosis Type 1 | NF1 | Von Recklinghausen DiseaseUnited States
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)United States
-
NYU Langone HealthCompletedNeurofibromatosis 1 and 2 (NF1 and NF2)United States
-
Vanderbilt UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingNeurofibromatosis Type 1 | Reading Disability | NF1 | Learning DisabilityUnited States
-
National Cancer Institute (NCI)CompletedParents of Children With Cancer | Parents of Children With NF1 | Parents of Children With Neurofibromatosis Type IUnited States, Canada
Clinical Trials on Cholecalciferol
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
Rashid Centre for Diabetes and ResearchCompletedObesity | Type 2 Diabetes Mellitus | Hypovitaminosis DUnited Arab Emirates
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexCompletedRenal Transplant Candidate for Right KidneyFrance